NCT01206972 - Dose-confirmatory Bridging Study in Total Knee Replacement | Biotech Hunter

Enrollment

302

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

June 30, 2011

Conditions

Venous Thromboembolism

Interventions

DRUG

Rivaroxaban (BAY59-7939)

daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)

DRUG

Rivaroxaban (BAY59-7939)

daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)

DRUG

Rivaroxaban (BAY59-7939)

daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)

DRUG

Enoxaparin

daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)

Trial Locations (33)

455-8530

Nagoya

271-8511

Matsudo

790-8524

Matsuyama

813-0017

Fukuoka

819-8551

Fukuoka

969-6593

Kawanuma

963-8501

Kōriyama

078-8237

Asahikawa

040-8611

Hakodate

060-8648

Sapporo

675-8545

Kakogawa

657-0068

Kobe

663-8501

Nishinomiya

305-0854

Tsukuba

602-8026

Kyoto

395-8505

Iida

857-8575

Sasebo

901-0243

Tomigusuku

573-8511

Hirakata

594-0071

Izumi

598-8577

Izumisano

596-8501

Kishiwada

596-8522

Kishiwada

530-0012

Osaka

558-8558

Osaka

599-8271

Sakai

589-8511

Sayama

569-1192

Takatsuki

849-8501

Saga

336-8522

Saitama

121-0064

Adachi City

177-8521

Nerima-ku

930-8550

Toyama